{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:26:50Z","timestamp":1768030010146,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stichting Bergh in het Zadel voor de Kankerbestrijding"},{"name":"Honderd-Duizend-keer-een-Tientje"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Angiosarcoma (AS) is a rare vasoformative sarcoma, with poor overall survival and a high need for novel treatment options. Clinically, AS consists of different subtypes, including AS related to previous UV exposure (UV AS) which could indicate susceptibility to DNA damage repair inhibition. We, therefore, investigated the presence of biomarkers PARP1 (poly(ADP-ribose)polymerase-1) and Schlafen-11 (SLFN11) in UV AS. Based on experiences in other sarcomas, we examined (combination) treatment of PARP inhibitor (PARPi) olaparib and temozolomide (TMZ) in UV AS cell lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Previously collected UV AS (<jats:italic>n<\/jats:italic>\u2009=\u200947) and non-UV AS (<jats:italic>n<\/jats:italic>\u2009=\u200996) patient samples and two UV AS cell lines (MO-LAS and AS-M) were immunohistochemically assessed for PARP1 and SLFN11 expression. Both cell lines were treated with single agents PARPi olaparib and TMZ, and the combination treatment. Next, cell viability and treatment synergy were analyzed. In addition, effects on apoptosis and DNA damage were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 46\/47 UV AS samples (98%), PARP1 expression was present. SLFN11 was expressed in 80% (37\/46) of cases. Olaparib and TMZ combination treatment was synergistic in both cell lines, with significantly increased apoptosis compared to single agent treatment. Furthermore, a significant increase in DNA damage marker \u03b3H2AX was present in both cell lines after combination therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We showed combination treatment of olaparib with TMZ was synergistic in UV AS cell lines. Expression of PARP1 and SLFN11 was present in the majority of UV AS tumor samples. Together, these results suggest combination treatment of olaparib and TMZ is a potential novel AS subtype-specific treatment option for UV AS patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03678-4","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T19:05:23Z","timestamp":1622747123000},"page":"2579-2590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PARP inhibition in UV-associated angiosarcoma preclinical models"],"prefix":"10.1007","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5737-7744","authenticated-orcid":false,"given":"Marije E.","family":"Weidema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid M. E.","family":"Desar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa H. S.","family":"Hillebrandt-Roeffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke E. M.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Masuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"PALGA-group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. R.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C. H.","family":"Hogenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta E.","family":"Flucke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winette T. A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne M. H.","family":"Versleijen-Jonkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"3678_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mds237","volume":"24","author":"M Agulnik","year":"2013","unstructured":"Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS (2013) An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol 24:257\u2013263. https:\/\/doi.org\/10.1093\/annonc\/mds237","journal-title":"Ann Oncol"},{"key":"3678_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603\u2013607. https:\/\/doi.org\/10.1038\/nature11003","journal-title":"Nature"},{"key":"3678_CR3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00109-019-01802-z","volume":"97","author":"X Cao","year":"2019","unstructured":"Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J, Wu Q, Park DM, Yang C (2019) Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med 97:1183\u20131193. https:\/\/doi.org\/10.1007\/s00109-019-01802-z","journal-title":"J Mol Med"},{"key":"3678_CR4","first-page":"19","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19\u201324","journal-title":"Cell Oncol"},{"key":"3678_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/jci139080","author":"JY Chan","year":"2020","unstructured":"Chan JY, Lim JQ, Yeong J, Ravi V, Guan P, Boot A, Tay TKY, Selvarajan S, Md Nasir ND, Loh JH, Ong CK, Huang D, Tan J, Li Z, Ng CC, Tan TT, Masuzawa M, Sung KW, Farid M, Quek RHH, Tan NC, Teo MCC, Rozen SG, Tan P, Futreal A, Teh BT, Soo KC (2020) Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma. J Clin Investig. https:\/\/doi.org\/10.1172\/jci139080","journal-title":"J Clin Investig"},{"key":"3678_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"key":"3678_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/1471-2407-14-813","volume":"14","author":"E Choy","year":"2014","unstructured":"Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D\u2019Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD (2014) Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 14:813. https:\/\/doi.org\/10.1186\/1471-2407-14-813","journal-title":"BMC Cancer"},{"key":"3678_CR8","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","volume":"34","author":"NJ Curtin","year":"2013","unstructured":"Curtin NJ, Szabo C (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Asp Med 34:1217\u20131256. https:\/\/doi.org\/10.1016\/j.mam.2013.01.006","journal-title":"Mol Asp Med"},{"key":"3678_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917\u2013921. https:\/\/doi.org\/10.1038\/nature03445","journal-title":"Nature"},{"key":"3678_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"SM Federico","year":"2020","unstructured":"Federico SM, Pappo AS, Sahr N, Sykes A, Campagne O, Stewart CF, Clay MR, Bahrami A, McCarville MB, Kaste SC, Santana VM, Helmig S, Gartrell J, Shelat A, Brennan RC, Hawkins D, Godwin K, Bishop MW, Furman WL, Stewart E (2020) A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer 137:204\u2013213. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.014","journal-title":"Eur J Cancer"},{"key":"3678_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","volume":"7","author":"V Florou","year":"2019","unstructured":"Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA (2019) Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 7:213\u2013313. https:\/\/doi.org\/10.1186\/s40425-019-0689-7","journal-title":"J Immunother Cancer"},{"key":"3678_CR12","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.21873\/anticanres.13501","volume":"39","author":"J Iwasaki","year":"2019","unstructured":"Iwasaki J, Komori T, Nakagawa F, Nagase H, Uchida J, Matsuo K, Uto Y (2019) Schlafen11 expression is associated with the antitumor activity of trabectedin in human sarcoma cell lines. Anticancer Res 39:3553\u20133563. https:\/\/doi.org\/10.21873\/anticanres.13501","journal-title":"Anticancer Res"},{"key":"3678_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0284186x.2016.1234068","volume":"56","author":"A Kollar","year":"2017","unstructured":"Kollar A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Grignani G, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litiere S, Marreaud S, Gronchi A, Kasper B (2017) Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncol 56:88\u201392. https:\/\/doi.org\/10.1080\/0284186x.2016.1234068","journal-title":"Acta Oncol"},{"key":"3678_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/10623320390272316","volume":"10","author":"V Krump-Konvalinkova","year":"2003","unstructured":"Krump-Konvalinkova V, Bittinger F, Olert J, Brauninger W, Brunner J, Kirkpatrick CJ (2003) Establishment and characterization of an angiosarcoma-derived cell line, As-M. Endothelium 10:319\u2013328","journal-title":"Endothelium"},{"key":"3678_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/SLA.0b013e3181dbb75a","volume":"251","author":"G Lahat","year":"2010","unstructured":"Lahat G, Dhuka AR, Hallevi H, Xiao L, Zou C, Smith KD, Phung TL, Pollock RE, Benjamin R, Hunt KK, Lazar AJ, Lev D (2010) Angiosarcoma: clinical and molecular insights. Ann Surg 251:1098\u20131106. https:\/\/doi.org\/10.1097\/SLA.0b013e3181dbb75a","journal-title":"Ann Surg"},{"key":"3678_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1634\/theoncologist.2015-0319","volume":"21","author":"L Leichman","year":"2016","unstructured":"Leichman L, Groshen S, O\u2019Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ, Gold P, Boman B, Fielding A, Locker G, Cason RC, Hamilton SR, Hochster HS (2016) Phase II study of olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer. Oncologist 21:172\u2013177. https:\/\/doi.org\/10.1634\/theoncologist.2015-0319","journal-title":"Oncologist"},{"key":"3678_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.Ccr-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM (2017) PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 23:523\u2013535. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1040","journal-title":"Clin Cancer Res"},{"key":"3678_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord CJ, Ashworth A (2012) The DNA damage response and cancer therapy. Nature 481:287\u2013294. https:\/\/doi.org\/10.1038\/nature10760","journal-title":"Nature"},{"key":"3678_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.pharmthera.2018.03.006","volume":"188","author":"Y Lu","year":"2018","unstructured":"Lu Y, Liu Y, Pang Y, Pacak K, Yang C (2018) Double-barreled gun: combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther 188:168\u2013175. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.006","journal-title":"Pharmacol Ther"},{"key":"3678_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cam4.12","volume":"1","author":"M Masuzawa","year":"2012","unstructured":"Masuzawa M, Masuzawa M, Hamada Y, Arakawa N, Mori M, Ishii M, Nishiyama S (2012) Establishment and characterization of a novel lymphangiosarcoma cell line (MO-LAS) compared with the hemangiosarcoma cell line (ISO-HAS). Cancer Med 1:39\u201346. https:\/\/doi.org\/10.1002\/cam4.12","journal-title":"Cancer Med"},{"key":"3678_CR21","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","volume":"26","author":"MR Middleton","year":"2015","unstructured":"Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM, Zhu M, Qian J, McKee M, Luo Y, Giranda VL, McArthur GA (2015) Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol 26:2173\u20132179. https:\/\/doi.org\/10.1093\/annonc\/mdv308","journal-title":"Ann Oncol"},{"key":"3678_CR22","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.Can-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588\u20135599. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-2753","journal-title":"Cancer Res"},{"key":"3678_CR23","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/jpet.113.210146","volume":"349","author":"J Murai","year":"2014","unstructured":"Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y (2014) Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349:408\u2013416. https:\/\/doi.org\/10.1124\/jpet.113.210146","journal-title":"J Pharmacol Exp Ther"},{"key":"3678_CR24","doi-asserted-by":"publisher","first-page":"76534","DOI":"10.18632\/oncotarget.12266","volume":"7","author":"J Murai","year":"2016","unstructured":"Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y (2016) Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7:76534\u201376550. https:\/\/doi.org\/10.18632\/oncotarget.12266","journal-title":"Oncotarget"},{"key":"3678_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","volume":"69","author":"J Murai","year":"2018","unstructured":"Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y (2018) SLFN11 blocks stressed replication forks independently of ATR. Mol Cell 69:371\u201384.e6. https:\/\/doi.org\/10.1016\/j.molcel.2018.01.012","journal-title":"Mol Cell"},{"key":"3678_CR26","unstructured":"NCIN (2012) National Cancer Intelligence Network. Soft tissue sarcoma incidence and survival; tumours diagnosed in England between 1985 and 2009. http:\/\/www.ncin.org.uk\/cancer_type_and_topic_specific_work\/cancer_type_specific_work\/sarcomas\/. Accessed 16 April 2012"},{"key":"3678_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41591-019-0749-z","volume":"26","author":"CA Painter","year":"2020","unstructured":"Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gomez Tejeda Zanudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, Van Tine BA, Lander ES, Golub TR, Wagle N (2020) The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med 26:181\u2013187. https:\/\/doi.org\/10.1038\/s41591-019-0749-z","journal-title":"Nat Med"},{"key":"3678_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdr138","volume":"23","author":"N Penel","year":"2012","unstructured":"Penel N, Italiano A, Ray-Coquard I, Chaigneau L, Delcambre C, Robin YM, Bui B, Bertucci F, Isambert N, Cupissol D, Bompas E, Bay JO, Duffaud F, Guillemet C, Blay JY (2012) Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol 23:517\u2013523. https:\/\/doi.org\/10.1093\/annonc\/mdr138","journal-title":"Ann Oncol"},{"key":"3678_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061502","author":"F Peyraud","year":"2020","unstructured":"Peyraud F, Italiano A (2020) Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers. https:\/\/doi.org\/10.3390\/cancers12061502","journal-title":"Cancers"},{"key":"3678_CR30","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1200\/jco.2018.77.7672","volume":"36","author":"MC Pietanza","year":"2018","unstructured":"Pietanza MC, Waqar SN, Krug LM, Dowlati A, Hann CL, Chiappori A, Owonikoko TK, Woo KM, Cardnell RJ, Fujimoto J, Long L, Diao L, Wang J, Bensman Y, Hurtado B, de Groot P, Sulman EP, Wistuba II, Chen A, Fleisher M, Heymach JV, Kris MG, Rudin CM, Byers LA (2018) Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol 36:2386\u20132394. https:\/\/doi.org\/10.1200\/jco.2018.77.7672","journal-title":"J Clin Oncol"},{"key":"3678_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12943-017-0652-5","volume":"16","author":"Y Pignochino","year":"2017","unstructured":"Pignochino Y, Capozzi F, D\u2019Ambrosio L, Dell\u2019Aglio C, Basirico M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G (2017) PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Mol Cancer 16:86. https:\/\/doi.org\/10.1186\/s12943-017-0652-5","journal-title":"Mol Cancer"},{"key":"3678_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","volume":"15","author":"D Rathkey","year":"2020","unstructured":"Rathkey D, Khanal M, Murai J, Zhang J, Sengupta M, Jiang Q, Morrow B, Evans CN, Chari R, Fetsch P, Chung HJ, Xi L, Roth M, Filie A, Raffeld M, Thomas A, Pommier Y, Hassan R (2020) Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression. J Thorac Oncol 15:843\u2013859. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.012","journal-title":"J Thorac Oncol"},{"key":"3678_CR35","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1634\/theoncologist.2011-0237","volume":"17","author":"I Ray-Coquard","year":"2012","unstructured":"Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N (2012) Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF\/GETO). Oncologist 17:260\u2013266. https:\/\/doi.org\/10.1634\/theoncologist.2011-0237","journal-title":"Oncologist"},{"key":"3678_CR36","doi-asserted-by":"publisher","first-page":"e28073","DOI":"10.1002\/pbc.28073","volume":"67","author":"ES Schafer","year":"2020","unstructured":"Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR, Romero JC, Hicks MJ, Nelson MD Jr, Voss S, Reid JM, Fox E, Weigel BJ, Blaney SM (2020) Phase 1\/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: a Children\u2019s Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer 67:e28073. https:\/\/doi.org\/10.1002\/pbc.28073","journal-title":"Pediatr Blood Cancer"},{"key":"3678_CR37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1078-0432.Ccr-14-2572","volume":"21","author":"MA Smith","year":"2015","unstructured":"Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ (2015) Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 21:819\u2013832. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2572","journal-title":"Clin Cancer Res"},{"key":"3678_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/annonc\/mdr066","volume":"23","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P, Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG (2012) Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 23:501\u2013508. https:\/\/doi.org\/10.1093\/annonc\/mdr066","journal-title":"Ann Oncol"},{"key":"3678_CR39","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/1078-0432.Ccr-14-2112","volume":"21","author":"SW Tang","year":"2015","unstructured":"Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y (2015) SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in Ewing sarcoma. Clin Cancer Res 21:4184\u20134193. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2112","journal-title":"Clin Cancer Res"},{"key":"3678_CR40","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/s0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879\u20131886. https:\/\/doi.org\/10.1016\/s0140-6736(12)60651-5","journal-title":"Lancet"},{"key":"3678_CR41","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00432-020-03211-z","volume":"146","author":"AEM van Erp","year":"2020","unstructured":"van Erp AEM, van Houdt L, Hillebrandt-Roeffen MHS, van Bree NFHN, Flucke UE, Mentzel T, Shipley J, Desar IME, Fleuren EDG, Versleijen-Jonkers YMH, van der Graaf WTA (2020) Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. J Cancer Res Clin Oncol 146:1659\u20131670. https:\/\/doi.org\/10.1007\/s00432-020-03211-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"3678_CR42","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.3892\/ol.2017.6892","volume":"14","author":"L Wang","year":"2017","unstructured":"Wang L, Lao IW, Yu L, Wang J (2017) Clinicopathological features and prognostic factors in angiosarcoma: a retrospective analysis of 200 patients from a single Chinese medical institute. Oncol Lett 14:5370\u20135378. https:\/\/doi.org\/10.3892\/ol.2017.6892","journal-title":"Oncol Lett"},{"key":"3678_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111780","author":"ME Weidema","year":"2019","unstructured":"Weidema ME, Flucke UE, van der Graaf WTA, Ho VKY, Hillebrandt-Roeffen MHS, Versleijen-Jonkers YMH, Husson O, Desar IME (2019) Prognostic factors in a large nationwide cohort of histologically confirmed primary and secondary angiosarcomas. Cancers. https:\/\/doi.org\/10.3390\/cancers11111780","journal-title":"Cancers"},{"key":"3678_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/1078-0432.CCR-19-2180","volume":"26","author":"ME Weidema","year":"2020","unstructured":"Weidema ME, van de Geer E, Koelsche C, Desar IME, Kemmeren P, Hillebrandt-Roeffen MHS, Ho VKY, van der Graaf WTA, Versleijen-Jonkers YMH, von Deimling A, Flucke UE (2020) DNA methylation profiling identifies distinct clusters in angiosarcomas. Clin Cancer Res 26:93. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2180","journal-title":"Clin Cancer Res"},{"key":"3678_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","volume":"124","author":"C Winkler","year":"2021","unstructured":"Winkler C, Armenia J, Jones GN, Tobalina L, Sale MJ, Petreus T, Baird T, Serra V, Wang AT, Lau A, Garnett MJ, Jaaks P, Coker EA, Pierce AJ, O\u2019Connor MJ, Leo E (2021) SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. Br J Cancer 124:951\u2013962. https:\/\/doi.org\/10.1038\/s41416-020-01199-4","journal-title":"Br J Cancer"},{"key":"3678_CR46","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1874467211205010102","volume":"5","author":"J Zhang","year":"2012","unstructured":"Zhang J, Stevens MF, Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5:102\u2013114","journal-title":"Curr Mol Pharmacol"},{"key":"3678_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz113","author":"C Zhang","year":"2019","unstructured":"Zhang C, Xu G, Liu Z, Xu Y, Lin F, Baklaushev VP, Chekhonin VP, Peltzer K, Mao M, Wang X, Wang G, Zhang C (2019) Epidemiology, tumor characteristics and survival in patients with angiosarcoma in the United States: a population-based study of 4537 cases. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyz113","journal-title":"Jpn J Clin Oncol"},{"key":"3678_CR48","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","volume":"109","author":"G Zoppoli","year":"2012","unstructured":"Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y (2012) Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci 109:15030. https:\/\/doi.org\/10.1073\/pnas.1205943109","journal-title":"Proc Natl Acad Sci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03678-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03678-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03678-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T10:09:56Z","timestamp":1627207796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03678-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3678"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03678-4","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"17 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for the use of patient material and data was obtained from the local certified Medical Ethics Committee of the Radboud University Medical Center, Nijmegen, The Netherlands (File number 2016-2686).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}